Published: 2 December 2023
Author(s): Carmen Álvarez-Reguera, Diana Prieto-Peña, Alba Herrero-Morant, Lara Sánchez-Bilbao, Ana Batlle-López, Sara Fernández-Luis, Nerea Paz-Gandiaga, Ricardo Blanco
Issue: May 2024
Section: Original Article

The Janus Kinase (JAK) 2 (V617F) mutation is the most frequently detected in myeloproliferative neoplasms (MPN). JAK2(V617F) mutation displays a pro-inflammatory phenotype that may be associated to a higher risk of immune mediated diseases (IMIDs), thromboembolic complications or other cancers. We aimed to evaluate the prevalence and main features of both rheumatic and non-rheumatic IMIDs in a cohort of MPNs patients with JAK2 (V617F) mutation.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.